1. Home
  2. Studies
  3. Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022 Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

German Economic Institute (IW) German Economic Institute (IW)

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

However, the German pharmaceutical industry sources most of its medicinal and chemical inputs either domestically or from other European countries. A similarly regional supply structure is to be found in the pharmaceutical and chemical sectors of those countries which supply the majority of intermediate inputs to Germany’s pharmaceutical industry, with those from China and India playing only a subordinate role. There is thus no evidence that German pharmaceutical production is predominantly dependent on these two Asian nations. However, since intermediate inputs are recorded by value, and prices for generic medicines and their active ingredients are much lower than those for innovative products, it is possible that despite China's small share of intermediate input purchases there may be a dependency in the case of certain individual generics. Nonetheless, a strategic boost to pharmaceutical production in Germany is scarcely to be achieved by expanding generic production. What is needed is rather a well-coordinated package of policy measures designed to encourage locally based firms to maintain and make long-term investments in their domestic production facilities and to promote the development of new innovative production. Such a course also pays off in terms of security of supply, since the patented innovative medicines of today are the generics of tomorrow.

Content element with id 10503
Download PDF
An International Comparison
Jasmina Kirchhoff IW-Trends No. 1 9. February 2022

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

German Economic Institute (IW) German Economic Institute (IW)

More on the topic

Read the article
The interplay of economic reasoning, voter preferences and party manifestos
Jochen Pimpertz / Ruth Maria Schüler IW-Analyse No. 156 10. June 2024

The Political Economy of Pension Reform

As the German population ages, the country’s statutory pension scheme, which is financed on a pay-as-you-go basis, requires higher and higher contributions while the level of pensions is falling.

IW

Read the article
Sebastian Dullien* / Simon Gerards Iglesias / Michael Hüther / Katja Rietzler* IW-Policy Paper No. 2 14. May 2024

Challenges for the debt brake

In 2019, Bardt et al. (2019) initially presented a comprehensive estimate of the unmet public investment needs in Germany not covered in household planning at the time, totaling around €460 billion over ten years.

IW

More about this topic

Content element with id 8880 Content element with id 9713